Clinical Trial Update: Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial of phenylbutyrate and genistein duotherapy in Delta F508-heterozygous cystic fibrosis patients was terminated, with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Genistein (genistein)
• Phenylbutyrate (phenylbutyrate)

Snippet

Sponsor: Children's Hospital of Philadelphia | Conditions: Cystic Fibrosis | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2011-06-30